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Amplification of the EMSY gene in sporadic breast
and ovarian cancers is a poor prognostic indicator.
Although EMSY has been linked to transcriptional
silencing, its mechanism of action is unknown. Here,
we report that EMSY acts as an oncogene, causing
the transformation of cells in vitro and potentiating
tumor formation and metastatic features in vivo.
We identify an inverse correlation between EMSY
amplification and miR-31 expression, an antimeta-
static microRNA, in the METABRIC cohort of human
breast samples. Re-expression of miR-31 profoundly
reduced cell migration, invasion, and colony-forma-
tion abilities of cells overexpressing EMSY or ha-
boring EMSY amplification. We show that EMSY is
recruited to the miR-31 promoter by the DNA binding
factor ETS-1, and it represses miR-31 transcription
by delivering the H3K4me3 demethylase JARID1b/
PLU-1/KDM5B. Altogether, these results suggest a
pathway underlying the role of EMSY in breast cancer
and uncover potential diagnostic and therapeutic
targets in sporadic breast cancer.
INTRODUCTION
The amplification of EMSY has been found in 17% and 13%
of sporadic ovarian and breast cancers, respectively, and it
is associated with a poor outcome (Brown et al., 2006, 2008,
2010; Hughes-Davies et al., 2003; Raouf et al., 2005; Rodriguez
et al., 2004). The EMSY (c11orf30) genemaps to 11q13-11q14, a806 Molecular Cell 53, 806–818, March 6, 2014 ª2014 The Authorslocus that harbors several known and potential oncogenic
drivers frequently amplified in breast cancer, most notably in
the estrogen-receptor-positive (ER+) luminal subtype. EMSY
was shown to silence BRCA2 transcriptional activity and localize
to sites of repair after DNA damage (Hughes-Davies et al., 2003).
Although the precise cellular function of EMSY remains un-
known, numerous lines of evidence suggest that EMSY plays a
role in transcriptional regulation. First, the N terminus of EMSY
has an evolutionarily conserved EMSY N-terminal domain that
structurally ressembles the DNA binding domain of homeo-
domain proteins (Chavali et al., 2005). Second, EMSY binds
chromatin-regulating factors such as HP1 (Ekblad et al., 2005;
Hughes-Davies et al., 2003). Third, EMSY was found as a
component of multiprotein complexes linked to transcriptional
control in D. melanogaster (Garapaty et al., 2009). Furthermore,
EMSY was involved in the repression of interferon (IFN)-stimu-
lated genes in a BRCA2-dependent manner (Ezell et al., 2012).
Finally, recent reports identify EMSY as part of the Nanog inter-
actome (Costa et al., 2013) as well as the SIN3B complexome
(Malovannaya et al., 2011).
MicroRNAs (miRNAs) are conserved small noncoding RNAs
that function as key negative regulators of gene expression.
Over the past years, a number of miRNAs were found to behave
as tumor suppressor genes or oncogenes (Garzon et al., 2009,
2006; Iorio et al., 2005). Classically, miRNAs are defined as tumor
suppressors genewhen they target an oncogene. Recent studies
have provided evidence for widespread deregulation of miRNA
in cancer leading to cell invasion, migration, and metastasis
(Bullock et al., 2012; Mirnezami et al., 2009; Visone and Croce,
2009). Likeother humangenes,miRNAexpression canbe altered
by several mechanisms, such as chromosomal abnormalities,
mutations, defects in their biogenesis machinery, epigenetic
silencing, or the deregulation of transcription factors (TFs)
(Kozaki et al., 2008; Lujambio et al., 2008; Saito et al., 2006).
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Figure 1. EMSY Overexpression Results in
Oncogenic Transformation
(A) EMSY increases anchorage-independent
growth in soft-agar assays. NIH 3T3 cells stably
transfected with human EMSY gene or an empty
vector were grown in soft agar for 14 days. Error
bars represent SD of the mean. Top, representa-
tive pictures of the colonies. Right, representative
western blot analysis of EMSY expression. Each
value is the average of three independent experi-
ments, and error bars display the SD of the mean.
(B) Soft-agar assay for MCF-7 cells stably over-
expressing EMSY or the empty vector. Results are
presented as in (A). Each value is the average of
three independent experiments, and error bars
display the SD of the mean.
(C) MCF-7-EMSY cells were injected into the
mammary fat pad of 5-week-old female athymic
nu/nu mice (n = 10). Mice were sacrificed 34 days
after injection, and then tumors were excised and
weighed. Quantifications of tumor volume (left) and
weight (middle) are shown. Right, representative
photographs of the tumors. Error bars display the
SD of the mean.
(D) MCF-7-EMSY cells induce micrometastasis in
the lungs after injection into the tail vein of 5-week-
old female athymic nu/nu mice (n = 10). Mice were
sacrificed 62 days after injection. Left, metastasis
was analyzed macroscopically and by H&E tis-
sue staining. Representative photographs of the
micrometastasis are shown, and arrows indicate
the micrometastasis. Right, quantifications of the
micrometastasis obtained. Error bars display the
SD of the mean.
See also Figure S1.
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The Breast Cancer Oncogene EMSY Represses miR-31Here, we identify several miRNAs whose expression varies
with EMSY expression levels. Among these, we find that miR-
31, an antimetastatic microRNA involved in breast cancer
(Valastyan et al., 2009a), is repressed by EMSY. Chromatin
immunoprecipitation (ChIP) experiments show that EMSY binds
to the miR-31 promoter. We demonstrate that the TF ETS-1 re-
cruits EMSY and that EMSY binding correlates with JARID1b/
PLU-1/KDM5B occupancy at the target promoter. Altogether,
our results identify EMSY as a regulator of miRNA gene expres-
sion and provide insights into the molecular mechanisms byMolecular Cell 53, 806–8which EMSY contributes to the initiation
or progression of breast cancer.
RESULTS
EMSY Exhibits All the Hallmarks of
an Oncogene
To determine the basis of EMSY’s
contribution to breast cancers, we asked
whether EMSY can induce malignant
transformation. First, we tested this by
stably transfecting mouse immortalized
fibroblast NIH 3T3 cells with the full-
length human EMSY coding sequence(Figure S1A available online). Figure 1A shows that EMSY over-
expression significantly confers the ability to NIH 3T3 fibroblasts
to form colonies in soft agar. Then, given that EMSY amplifica-
tions are observed predominantly in luminal breast tumors, we
engineered the luminal breast cancer MCF-7 cell line, which har-
bors normal levels of EMSY, to stably overexpress EMSY (MCF-
7-EMSY) and similarly tested the oncogenic activity of several
clones using the soft-agar assay. We confirmed EMSY overex-
pression by western blotting and quantitative real-time PCR
(qRT-PCR; Figures S1B and 1B). Figure 1B shows that EMSY18, March 6, 2014 ª2014 The Authors 807
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The Breast Cancer Oncogene EMSY Represses miR-31overexpression significantly enhances anchorage-independent
growth of MCF-7 cells. This effect is unlikely to be due to an in-
crease in proliferation, given that no differences in growth rate
could be detected between the MCF-7 and MCF-7-EMSY cell
lines (Figure S1C).
To further investigate the tumorigenic capacity of EMSY, we
set out to determine whether EMSY affects tumor growth in vivo.
To this end, equal numbers of mock- and EMSY-expressing
MCF-7 cells were orthotopically implanted into the mammary
fat pad of athymic nu/nu mice, and the animals were monitored
twice a week over 34 days. MCF-7 cells are poorly invasive and
metastatic, but EMSY-transformed cells produced tumors first
measurable after 12 days and that continued to grow in size until
the termination of the experiment. In contrast, no tumors were
detected in MCF-7 control cells (Figure 1C). Finally, EMSY was
demonstrated to increase the metastatic potential of MCF-7
cells, given that mice injected in the tail vein with MCF-7-
EMSY cells developed more lung micrometastases than those
injected with controls cells. Histological staining of the lungs
were observed andmicrometastasis were quantified (Figure 1D).
Altogether, these results establish EMSY as a potent breast can-
cer oncogene in vitro and in vivo.
EMSY Affects miRNA Expression
In order to understand the mechanisms by which EMSY induces
oncogenic transformation, and given its potential to regulate
transcription (Hughes-Davies et al., 2003), we sought to identify
genes regulated by EMSY. We considered the possibility that
EMSY may regulate the expression of critical miRNAs, given
that certain miRNAs are associated with poor breast cancer
outcome, similar to EMSY amplification (Garzon et al., 2009; Iorio
and Croce, 2009; Iorio et al., 2005; Lujambio et al., 2008). First,
we performed an unbiased screen to identify miRNAs whose
expression may vary with EMSY levels. Using a qPCR-based
array, we profiled the expression of 88 miRNAs known or pre-
dicted to alter their expression during breast cancer initiation
and/or progression in MCF-7 cells depleted from EMSY using
small interfering RNA (siRNA). We found 38 significantly deregu-
lated miRNAs (9 downregulated and 29 upregulated; Table S1).
Then, we asked whether these potential EMSY targets would
also be deregulated in tumors where EMSY is amplified. Thus,
we investigated miRNA expression within the Molecular Taxon-
omy of Breast Cancer International Consortium (METABRIC)
cohort of human breast cancer samples (Curtis et al., 2012)
(Table S2). The integrated analysis of genomic copy numberFigure 2. Expression of EMSY Anticorrelates with miR-31 Levels In Vit
(A) Box plots illustrating the distribution of EMSY copy-number-segmented mea
for 1,283 tumors from the METABRIC cohort (see also Table S1).
(B) Box plot of miR-31 expression for cases with EMSY amplification (AMP; n =
p value was determined by a Wilcoxon rank-sum test.
(C) EMSY represses miR-31 transcription. qRT-PCR analysis of mature forms of
Error bars represent SD of the mean.
(D) Left, relative expression levels of miR-31, miR-198, andmiR-181-a2 determine
Error bars represent SD of the mean. Right, representative western blot ana
human EMSY.
(E) Relative expression of the miR-31-regulated prometastatic genes upon EMSY
Error bars represent SD of the mean.
See also Figure S2.
Mand gene expression revealed an ER+ subgroup (IntClust 2;
3.6% of cases) with cis-acting aberrations at the 11q13-11q14
locus (containing EMSY) and extremely poor outcome. In line
with our previous findings (Hughes-Davies et al., 2003), the
11q13-11q14 cis-acting group (IntClust 2; Figures 2A and S2A)
was enriched for EMSY amplification. EMSY copy-number alter-
ations occur predominantly in ER+ tumors (91.13% of the EMSY
amplified cases are ER+; 7.59%of the EMSY amplified cases are
ER; 73.4% of the entire cohort is ER+; IntClust 2; Figure 2A).
The miRNA expression levels were available for 1,283 samples
from this cohort. We compared EMSY-amplified versus neutral
cases from the METABRIC data set and found that 12 miRNAs
were significantly deregulated (six downregulated and six upre-
gulated; Benjamini-Hochberg adjusted p value < 0.05; Table S3).
Given that miR-31 was the only common target identified from
these two approaches (downregulated in EMSY amplified cases
and upregulated in cells depleted from EMSY) and that miR-31
has been previously reported as amicroRNA involved in the sup-
pression of metastasis in breast cancer (Valastyan et al., 2009a,
2009b, 2010, 2011; Valastyan and Weinberg, 2010, 2011), we
considered the possibility that miR-31 is an EMSY target gene
and that it may be part of the mechanism underpinning EMSY’s
oncogenic potential. Therefore, we decided to focus our interest
on this microRNA.
Next, we set out to further confirm the observation that miR-31
expression levels are significantly lower in EMSY-amplified
versus neutral tumors (Figure 2B; p value < 0.001; Wilcoxon
rank-sum test). Given that the expression probe for EMSY on
the Illumina HT12 v3 array was nonresponsive, we profiled
miR-31 expression levels by qRT-PCR in a representative subset
of 98 primary tumors from the METABRIC cohort. This analysis
corroborates our previous findings, given that EMSY copy-num-
ber and expression levels were highly correlated (r = 0.795,
Spearmann’s rho; p value < 0.0001). We found that EMSY
expression strongly anticorrelated with miR-31 expression
(r = 0.732, Spearmann’s rho; p value < 0.0001; Figures S2B
and S2C). Then, we further examined the relationship between
EMSY and miR-31 expression levels. The expression of miR-
31 was monitored by qRT-PCR in MCF-7 cells overexpressing
EMSY and in comparison to control cells. This analysis revealed
that miR-31 levels were significantly reduced in cells stably
overexpressing EMSY, whereas the expression of other miRNAs
such as miR-181a-2 and miR-198 remained unchanged (Fig-
ure 2C). Conversly, and consistent with these findings, miR-31
was markedly upregulated in EMSY-depleted MCF-7 cellsro and In Vivo
ns across the integrative subgroups (left) and PAM50 intrinsic subtypes (right)
45, red boxes) versus neutral copy numbers (NEUT; n = 809, blue boxes). The
the indicated miRNAs in MCF-7 cells stably overexpressing EMSY or control.
d by qRT-PCR in MCF-7 cells transfected with siRNAs targeting human EMSY.
lysis of EMSY expression in MCF7 cells transfected with siRNAs targeting
overexpression inMCF-7 cells. Transcripts levels were measured by qRT-PCR.
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The Breast Cancer Oncogene EMSY Represses miR-31(Figure S2E), in comparison to miR-181a-2 and miR-198 (Fig-
ure 2D). Finally, we evaluated miR-31 levels in tumors obtained
from the mammary fat pad experiment presented in Figure 1C.
Figure S2D shows that miR-31 expression is lower in tumors
generated from theMCF-7-EMSY than fromMCF-7 control cells.
Altogether, these results support an inverse correlation between
EMSY and miR-31 expression levels.
Given that miR-31 affects cell invasion and migration via its
pleiotropic regulation of prometastatic target genes (Valastyan
et al., 2009b), we tested whether EMSY expression impacts
on miR-31 target genes. To test this, we analyzed MCF-7 cells
stably overexpressing EMSY (Figures 1B and S1B) for the
expression of a set of validated miR-31 target genes (Valastyan
et al., 2009a, 2009b). Figure 2E shows that MCF-7-EMSY cells
display higher levels of transcripts reported to be under the
control of miR-31 (RhoA, RDX, ITGA5, M-RIP, FZD3, and
MMP16) in comparison to control cells. This effect is specific,
given that non-miR-31 target transcripts, namely B2M,
CXCL12, and ALAS1, remain unaffected (Figure 2E). Three
miR-31 target genes, namely ITGA5, RDX, and RhoA, are crucial
for the antimetastatic response of miR-31 (Valastyan et al.
2009a, 2009b).
miR-31 Reverts EMSY Oncogenicity In Vitro
Then, we set out to test whether EMSY overexpression impacts
on the invasive and migrative capability of MCF-7 cells. Using a
Boyden chamber assay, we observed that the overexpression of
EMSY increases MCF-7 migrative capacity when compared
to control cells (Figure 3A). These findings are consistent with
the results obtained from the mammary fat pad and tail vein in-
jection experiments described in Figure 1. Then, to establish
whether miR-31 mediates, at least in part, the effects of EMSY
overexpression, we performed a ‘‘rescue’’ experiment wherein
miR-31 was exogenously expressed in the context of EMSY
overexpression. MCF-7 cells stably overexpressing EMSY
were transfected with a vector encoding miR-31. Enforced
expression of miR-31 significantly reversed EMSY-mediated in-
duction of cell migration (Figure 3A). Given that miR-31 has been
described to affect invasion and migration (Valastyan et al.,
2009b, 2010), we tested whether miR-31 inhibition alters the
initial acquisition of a transformed phenotype. We used anti-
sense oligonucleotides to deplete MCF-7 cells from miR-31.
We found that a loss of miR-31 significantly enhanced the inva-
sion and migration capacity of MCF-7 cells (Figure 3B). Howev-
er, when miR-31 sponges were used to stably deplete miR-31Figure 3. miR-31 Reverts EMSY Oncogenicity In Vitro
(A) Invasion and migration assay of MCF-7 cells stably expressing EMSY. Reintro
the mean.
(B) Invasion and migration assay of MCF-7 cells transiently depleted frommiR-31
by qRT-PCR.
(C) Stable depletion of miR-31 reduces anchorage-independent growth of MCF-
(D) Soft-agar assay of MCF-7 cells stably overexpressing EMSY after the reintro
(E) The expression levels of the indicated miRNAs were measured by qRT-PCR in
Error bars represent SD of the mean.
(F) Soft-agar assay of MDA-MB-175 cells stably depleted from EMSY.
(G) Exogenous expression of miR-31 reduces anchorage-independent growth o
(H) Invasion and migration assay of MDA-MB-175 cells either stably depleted from
*p < 0.05, **p < 0.01, and ***p < 0.001. See also Figure S3.
Mfrom MCF-7 cells, we observed that the resulting cells formed
colonies in soft agar as efficiently as control MCF-7 cells (Fig-
ure 3C). Thus, the loss of miR-31 from MCF-7 cells did not
enhance transformation. These data indicate that EMSY overex-
pression induces MCF-7 cell transformation, and, in a second
step, EMSY functions to downregulate miR-31, leading to the
progression of the transformed phenotype (i.e., the acquisition
of traits such as invasion and migration). Importantly, these
data are completely consistent with those reported by Valastyan
et al. (2009b) and led us to propose a model for the EMSY-miR-
31 interaction. Then, we asked whether the re-expression of
miR-31 in MCF-7 cells stably overexpressing EMSY could abro-
gate EMSY-induced oncogenic activity using the soft-agar
assay. Figure 3D shows that miR-31 re-expression profoundly
reduces the ability of the MCF-7-EMSY cells to form colonies
in soft agar.
Next, having shown that EMSY and miR-31 levels inversely
correlate in human breast cancers, we investigated whether
the EMSY-miR-31 interaction is also seen in cell lines harboring
amplification of the EMSY-11q13-11q14 locus. We used two
such cell lines, MDA-MB-175 and MDA-MB-415 (Rodriguez
et al., 2004), and confirmed that both have high EMSY and
very low miR-31 levels in comparison to MCF-7 cells (Fig-
ure S3A). Figure 3E shows that miR-31 was markedly upregu-
lated in MDA-MB-175 cells upon EMSY depletion, consistent
with our results in MCF-7 cells (Figure 2C). Similar results
were obtained in MDA-MB-415 cells (Figure S3B). Then, we
tested the oncogenic activity of these cells in vitro using the
soft-agar assay. EMSY depletion significantly reduces the
anchorage-independent growth of both cell lines (Figures 3F
and S3D). Moreover, increased expression of miR-31 pheno-
copies the effect of EMSY knockdown in these two EMSY-
amplified cell lines (Figures 3G and S3E). Finally, we monitored
the invasion and migration abilities of MDA-MB-175 and MDB-
MB-415 cells after the depletion of EMSY or overexpression
of miR-31. EMSY depletion significantly reduced the invasion
and migration abilities of the cell lines (Figures 3H and S3F).
Exogenous expression of miR-31 reduced the invasive and mi-
grative rates of both cells lines (Figures 3H and S3F). Therefore,
we conclude that miR-31 expression phenocopies the effect of
EMSY depletion. Altogether, these results indicate that the in-
vasion and migration features of EMSY-amplified breast cancer
cells are dependent on EMSY levels. These results also demon-
strate that miR-31 is an important antagonist of EMSY’s func-
tion in breast cancer.duction of miR-31 reduces EMSY-mediated effects. Error bars represent SD of
using oligonucleotides. Bottom, relative expression levels of miR-31 measured
7 cells. Error bars represent SD of the mean.
duction of miR-31. Results are presented as in (C).
MDA-MB-175, harouring EMSY amplification, and stably depleted from EMSY.
f of MDA-MB-175. Results are presented as in (C).
EMSY or stably overexpressing miR-31. Error bars represent SD of the mean.
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Figure 4. EMSY Represses miR-31 Transcription and Associates to
miR-31 Promoter
(A) pri-miRNAs level determined by qRT-PCR in MCF-7 cells transiently
depleted from EMSY. Error bars display SD of the mean.
(B) EMSY associates to miR-31 promoter. ChIP in MCF-7 cells treated with
control siRNA or EMSY siRNA using anti-EMSY or anti-GFP (control). The data
have been normalized to ‘‘input DNA’’ amplification levels for each amplicon.
Each amplicon was analyzed in duplicate. Experiments were repeated at least
two times with similar results. A representative example of a ChIP analysis is
shown. Error bars display the SD of the mean.
(C) EMSY depletion leads to increased levels of RNA polymerase II at miR-31
promoter. ChIPwith anti-RNA polymerase II inMCF-7 cells treatedwith control
siRNA or EMSY siRNA. Results are presented as in (B).
(D) EMSY and RNA polymerase II occupancy at the miR-31 promoter were
assessed in MCF-7, MDA-MB-175, and MDA-MB-415 cells. Results are pre-
sented as in (B).
See also Figure S4.
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miR-31 Promoter
EMSY is not listed as a putativemiR-31 target, and its expression
remained constant upon miR-31 transfection (data not shown).
In contrast, the depletion of EMSY led to increased levels of pri-
mary miR-31 transcripts (pri-miR-31; Figure 4A) suggesting that
EMSY affects the transcription of the miR-31 gene rather than
the processing of its transcripts. These observations prompted
us to investigate whether EMSY directly represses transcription
of miR-31 by binding to its promoter region. We identified the
promoter of miR-31 using 50 rapid amplification of complemen-
tary DNA (cDNA) ends (RACE) experiments (Figure S4A). ChIP
analyses indicated that EMSY associated with the promoter of
miR-31 but did not bind the regions upstream of two control
miRNA genes, miR-181a-2 and miR-198 (Figures 4B and S4B).
Furthermore, we found that RNA polymerase II occupancy
on the miR-31 promoter increased upon the downregulation
of EMSY, consistent with EMSY repressing transcription (Fig-
ure 4C). Finally, to address whether EMSY amplification could
further repress miR-31, as predicted by our previous results,
we compared EMSY and RNA polymerase II occupancy
between MCF-7 cells (which exhibit normal EMSY levels) and
MDA-MB-415 and MDA-MB-175 cells (which exhibit amplifica-
tion of the EMSY gene). EMSY occupancy on the miR-31 pro-
moter was higher in cells with EMSY amplification, whereas
RNA polymerase II occupancy was lower (Figure 4D). Altogether,
these observations indicate that EMSY associates with the
promoter of miR-31 and represses its expression.
The Transcription Factor ETS-1 Recruits EMSY to the
miR-31 Promoter
To further understand the mechanisms by which EMSY silences
miR-31, we sought to decipher how EMSY is recruited to the
miR-31 promoter. Given that EMSY has no obvious DNA bind-
ing domain, we considered the possibility that EMSY is re-
cruited to the promoter of miR-31 via a DNA binding TF. To
probe this hypothesis, we tested whether BRCA2, a known
binding partner of EMSY (Hughes-Davies et al., 2003), may be
involved in EMSY’s recruitment. The depletion of BRCA2 has
no effect on miR-31 expression, indicating that BRCA2 is not
directly involved in the EMSY/miR-31 pathway (Figure S4C).
Then, we examined the DNA sequence upstream of the miR-
31 transcription start site for TF binding sites. Figure 5A shows
that putative binding sites for ETS family members (ETS-1 and
ETV4/PEA3) can be found in the miR-31 regulatory region but
not within the analogous regions of miR-198 and miR-181a-2,
whereas a GATA1 site is present within miR-31 and miR-198.
The position weight matrix (PWM) for the ETS-1 TF binding motif
was identified from the JASPAR database (http://jaspar.
genereg.net). The presence of the ETS-1 binding motif in the
miRNA promoters was confirmed with the matchPWM function
in the Biostrings package with a minimum matching score of
100%. Importantly, ETS-1 is a classic DNA binding protein
implicated in transcriptional regulation, and its expression
correlates with higher incidence of metastasis and poorer
prognosis in breast and ovarian carcinoma (Buggy et al.,
2004; Furlan et al., 2008; Gilles et al., 1997). In order to validate
the TF binding site predicions, we depleted MCF-7 cells for
Molecular Cell
The Breast Cancer Oncogene EMSY Represses miR-31each of the TFs with a putative binding site in the miR-31 pro-
moter (ETS-1, ETV4, and GATA1) and assessed the expression
of miR-31. Figures 5B and S5A show that, of the three TFs,
only ETS-1 downregulation led to the specific upregulation of
miR-31. Importantly, it did so without affecting the expression
of miR-198 and miR-181a-2. To further confirm these results
and validate the predictions from the bioinformatic analyses,
we tested the ETS-1 motifs in the miR-31 cis-regulatory element
in functional transcription assays. We constructed reporter vec-
tors containing the miR-31 promoter sequence upstream of
the firefly luciferase cDNA using the pGL4 plasmid. Figure 5C
shows promoter activity for the miR-31 promoter region con-
taining the 2 ETS-1 motifs. Site-directed mutagenesis of each
of the ETS-1 sites (site 218, TTTCCG was mutated into TTTTTT,
and site 512, CTTCCG was mutated into TTTTTT) led to a signif-
icant increase of promoter activation (Figure 5C). These results
demonstrate that each of the ETS-1 binding sites are relevant to
miR-31 expression and that ETS-1 functions as a repressor in
this context. The mutation of both ETS-1 binding sites (218
and 512) did affect miR-31 promoter activity more than each
of the single mutants. Importantly, we confirmed by ChIP that
the ETS-1 protein binds directly to the miR-31 promoter within
the region containing the predicted ETS binding site (Figure 5D).
This analysis also showed that ETS-1 did not bind to other
regions within the miR-31 promoter, nor did it bind to the pro-
moters of miR-181a-2 or miR-198 (Figure S5C). Furthermore,
depletion of ETS-1 resulted in reduced binding of both ETS-1
and EMSY to the miR-31 promoter (Figure 5D) without affecting
the levels of EMSY protein in MCF-7 cells (Figure S5B). Notably,
downregulation of EMSY does not affect the binding of ETS-1
to the miR-31 promoter, supporting a model in which ETS-1
recruits EMSY to the miR-31 promoter.
The Histone H3K4me3 Demethylase KDM5b Interacts
with EMSY and Contributes to miR-31 Silencing
EMSY has been found to be a component of complexes involved
in transcriptional control that contain, among other proteins,
members of the histone H3K4me3 demethylase family (Barrett
et al., 2002, 2007; Moshkin et al., 2009). Given that JARID1b/
PLU1/KDM5B has been shown to be expressed in 90% of
invasive ductal carcinomas and that KDM5B represses tran-
scription by demethylating H3K4 (Barrett et al., 2002, 2007; Lu
et al., 1999; Yamane et al., 2007), we examined whether
KDM5B associates with EMSY. Figure 5E shows that KDM5B
coimmunoprecipitates with endogenous EMSY from MCF-7
cell extracts. Moreover, ChIP experiments showed that
KDM5B binds to the miR-31 promoter at the same position as
EMSY and ETS-1 (Figures 5F and S5E). Consistent with its role
as a histone demethylase, the depletion of KDM5B (Figure S5D)
resulted in an increase of H3K4 trimethylation on themiR-31 pro-
moter (Figure 5F) and a concomitant increase in the expression
of miR-31 (Figure 5G). Depletion of KDM5B did not affect the
association of either EMSY or ETS-1 to the miR-31 promoter
but did affect its own binding in that region (Figure 5F).
Finally, we asked whether ETS-1 and KDM5B contribute
to EMSY’s capacity to increase the migration of MCF-7 cells.
Using the Boyden chamber assay, we observed that the
increased migrative ability of MCF-7 cells overexpressingMEMSY is significantly reduced when cells are depleted for
ETS-1, KDM5B, or a combination of both ETS-1 and KDM5B
(Figure 5H). Altogether, these results support a model
whereby ETS-1 directly binds to an ETS binding motif within
the miR-31 promoter to recruit EMSY and KDM5B to repress
transcription.
DISCUSSION
The EMSY gene is amplified and overexpressed in a substantial
proportion of sporadic cases of poor prognosis breast cancer.
However, determining the direct contribution of EMSY to breast
cancer has been difficult because the gene resides within the
11q13-11q14 locus, containing a cassette of genes, including
several known and potential breast cancer drivers (CCND1,
PAK1, andRSF1). This hasmeant that EMSY’s oncogenic contri-
bution has been difficult to assess. Our previous studies have
shown that the EMSY protein interacts with BRCA2 and has a
role in chromatin remodeling (Hughes-Davies et al., 2003). The
data presented here show that EMSY itself possesses the hall-
marks of an oncogene: ectopic expression of EMSY transforms
NIH 3T3 fibroblasts, confers anchorage-independent growth to
MCF-7 cells in soft agar, and potentiates tumor formation and
metastatic features in vivo (Figure 1). In light of the recent
demonstration that amplification of the 11q13-11q14 locus is
associated with a particularly high-risk outcome (Curtis et al.,
2012), the results presented here support the conclusion that
EMSY is not simply a passenger of the locus but rather a signif-
icant oncogenic driver.
Our results also identify a subset of miRNAs whose expres-
sion is affected by EMSY levels in primary breast tumor
samples. One of them, miR-31, is a key regulator of breast can-
cer metastasis. Examination of the large METABRIC cohort
highlights a negative correlation between EMSY and miR-31
expression. In breast cancer cell lines, the overexpression of
EMSY reduces the expression of the miR-31 gene, increases
the expression of miR-31 target genes, and induces invasion
and migration. We also find that loss of miR-31 did not enhance
transformation in MCF-7 cells, suggesting a two-step process,
wherein EMSY overexpression induces cell transformation and
then EMSY functions to downregulate miR-31, leading to the
progression of the transformed phenotype (i.e., the acquisition
of traits such as invasion and migration). Moreover, restoration
of miR-31 significantly inhibited the invasion, migration, and
colony-formation abilities of cells overexpressing EMSY or
harboring EMSY amplification, a result which phenocopied the
effects of EMSY depletion in these cells. Thus, the regulation
of the miR-31 pathway by EMSY can explain, at least in part,
its oncogenic behavior and association with poor prognosis
(Figure 3). Moreover, miR-31 is a critical target of EMSY in
breast cancer. Our results also identify an EMSY pathway
in which the BRCA2 protein does not seem to contribute.
Therefore, the work presented here provides evidence for the
existence of at least two distinct EMSY activities: one where
EMSY acts in concert with BRCA2, and one where EMSY func-
tions in a BRCA2-independent manner.
Our data also provide mechanistic insights into the function of
EMSY at the molecular level. EMSY is recruited to the miR-31olecular Cell 53, 806–818, March 6, 2014 ª2014 The Authors 813
N
or
m
al
iz
ed
 m
iR
NA
 e
xp
re
ss
io
n 
miR-31
1
2
0
miR-198 miR-181a-2
si control
si ETS1
si ETV4
si GATA1
3
B
A
miR-31
-
22
8
-
51
2
AGGAAGTACTTCCG
miR-198
miR-181a-2
ETS-1ETS-1GATA ETV4
..........TGTGATAGCCGC...
-
55
7
..........CCTTTCCGCGGC...
GATA
..........CTGATAAC...
-
20
GATA
..........CAGATAACTT
-
90
luc
ETS-1
-228-512
ETS-1
pGL4 controlluc
luc
ETS-1
-228-512
ETS-1
luc
ETS-1
-228-512
ETS-1
mut512
mut228&512
luc
ETS-1
-228-512
ETS-1 miR-31 WT
mut228X
X
X
X
si control
si ETS-1
R
el
at
iv
e 
en
ric
hm
en
t t
o 
In
pu
t
ChIP ab: GFP
0,002
0,006
0,010
0,008
0,004
0
ETS-1 EMSY
ChIP on miR-31 promoter
si control
si KDM5B
R
el
at
iv
e 
en
ric
hm
en
t t
o 
In
pu
t
ChIP ab: GFP KDM5B ETS-1EMSY
0,002
0,006
0,010
0,008
0,004
0
H3K4me3
0,5
1,5
2,5
2,0
1,0
0
F
N
or
m
al
iz
ed
 m
iR
NA
 
e
xp
re
ss
io
n
14
10
0
12
6
8
4
2
si control
si KDM5B-1
si KDM5B-2
EMSY
14
0
8
12
4
2
10
6
- -- + + +
Fo
ld
 In
va
si
on
/ M
ig
ra
tio
n
+
HG
anti-EMSY
anti-KDM5B
In
pu
t
G
FP
ET
S-
1
K
D
M
5B
SU
Z1
2
EM
SY
anti-ETS1
IP
C
D E
RLU (relative luciferase unit) 
500 10 20 30 40 7060
*
*
*
*
*
*
*
*
*
ChIP on miR-31 promoter
** **
** **
**
***
Figure5. EMSY IsRecruited to themiR-31Promoter viaETS-1TranscriptionFactor and InteractswithH3K4me3HistoneDemethylaseKDM5B
(A) Schematic view of the indicated miRNA promoter region (1,000 bp upstream from the putative transcription start site; arrow). The locations of predicted
putative TF binding sites are shown for ETS-1, ETV4 (PEA3), and GATA1. Numbering is relative to the transcription start site.
(legend continued on next page)
Molecular Cell
The Breast Cancer Oncogene EMSY Represses miR-31
814 Molecular Cell 53, 806–818, March 6, 2014 ª2014 The Authors
Molecular Cell
The Breast Cancer Oncogene EMSY Represses miR-31promoter by the ETS-1 TF, and, together with the KDM5B
histone demethylase, these factors repress miR-31 expression
(Figure 5). The ability of EMSY to function via the recruitment
of the chromatin regulator KDM5B is consistent with its previ-
ously suspected involvement in chromatin regulation (Ekblad
et al., 2005; Garapaty et al., 2009; Hughes-Davies et al., 2003;
Moshkin et al., 2009; Yao and Polyak, 2004). Furthermore, it is
interesting to note that two components of this pathway, namely
ETS-1 and KDM5B, have themselves been implicated in breast
cancer (Buggy et al., 2004; Yamane et al., 2007). Of particular
relevance is the fact that ETS-1 is defined as a candidate breast
cancer oncogene involved in the regulation of the expression of
genes involved in tumor progression and metastasis (Switzer
et al., 2012) and that the expression of ETS-1 correlates with
higher incidence of metastasis and poorer prognosis in breast
and ovarian carcinoma (Buggy et al., 2004; Furlan et al., 2008;
Gilles et al., 1997). The second factor implicated in the pathway,
which we identified as KDM5B, is an H3K4me2- and H3K4me3-
specific demethylase belonging to the Jmjc-domain-containing
family of histone demethylase. KDM5B has been shown to
be overexpressed in several cancers, such as breast, prostate,
and lung cancer, and is required for mammary tumor formation
in xenograft mouse models (Catchpole et al., 2011; Yamane
et al., 2007).
The pathway indentified here (EMSY/ETS1/KDM5B/miR-31)
may not provide the unique and complete molecular explana-
tion for the association between EMSY amplification and poor
prognosis. EMSY’s contribution to tumorigenesis may not be
solely due to the silencing of miR-31, given that other EMSY un-
identified target genes may also play a role. As such, the iden-
tification of additional EMSY mRNAs and miRNA targets will be
important for understanding the complex mechanisms underly-
ing EMSY’s role in breast cancer. Moreover, the EMSY/ETS-1/
KDM5B pathway may not be the only route for miR-31 tran-
scriptional regulation. Indeed, recent reports have identified
other genetic and epigenetic axes influencing miR-31 expres-
sion (Augoff et al., 2012; Yamagishi et al., 2012). For example,
in adult T cell leukemia, Polycomb proteins have been shown
to contribute to miR-31 downregulation (Yamagishi et al.,
2012). Interestingly, a functional interplay between KDM5B
and Polycomb proteins has recently been implicated in mouse
development (Albert et al., 2013). In addition, another epigenetic
modification, DNA methylation, is also involved in decreasing(B) Expression of the miR-31, miR-198, and miR-181a-2 genes were studied by
siRNAs. Error bars represent SD of the mean.
(C) MCF-7 cells were transiently transfected with the cis-regulatory element of mi
scheme (left). The luciferase activity of empty pGL4 was used as the control. Lu
the level of Renilla luciferase activity and then to control RLU (empty vector). Site-
ETS-1 binding sites. Error bars represent SD of the mean.
(D) Chromatin from MCF-7 cells depleted from ETS-1 was immunoprecipitated w
(E) Endogenous coimmunoprecipitation assays for detecting the interaction be
immunoprecipitated with anti-ETS-1, anti-KDM5B, anti-SUZ12, and anti-EMSY
KDM5B in immunoprecipitates was detected by western blotting.
(F) KDM5B depletion affects H3K4me3 levels on miR-31 promoter. ChIP in contr
(G) The expression levels of mature forms of the indicated miRNAs were measur
(H) Migration assay of MCF-7 cells overexpressing EMSYor an empty vector after
Error bars represent SD of the mean.
*p < 0.05, **p < 0.01, and ***p < 0.001. See also Figure S5.
MmiR-31 expression in breast cancer (Vrba et al., 2013). The
interplay between EMSY and these factors, in addition to other
targets and/or signals such as estrogen, and how they may
contribute to malignant progression are of significant interest
for future work.
The data presented here, which are derived from multiple
different molecular and cellular assays as well as animal studies
together with correlative studies involving human breast cancer
patients, collectively and consistently support the conclusion
that EMSY represses transcription of the noncoding miR-31
gene. This pathway represents one mechanism by which
EMSY exerts its oncogenic and metastatic potential in breast
cancer, resulting in a poor outcome prognosis of EMSY-ampli-
fied breast tumors. Given the convergence of four breast-can-
cer-associated genes (EMSY, ETS-1, KDM5B, and miR-31)
with overlapping biological roles, this pathway offers a number
of avenues for therapeutic intervention.
EXPERIMENTAL PROCEDURES
The details of all siRNAs, plasmids, synthetic RNAs, primers, and antibodies
used in this study are provided in in the Supplemental Information and/or
are available upon request.
Cell Culture
Mouse NIH 3T3 and human breast cancer cell lines MCF-7, MDA-MB-415,
and MDA-MB-175 were purchased from ATCC and cultured in Dulbecco’s
modified Eagle’s medium (DMEM; Invitrogen) supplemented with 10% fetal
bovine serum (FBS; Gibco) and 1% penicillin and streptomycin and grown at
37C under 5% CO2.
Xenograft Assay and Tail Vein Injection
In this study, 5-week-old female athymic nu/nu mice (Harlan Laboratories)
housed under specific pathogen-free conditions were used. Mice were
anesthetized and ovariectomized 2 days before the implantation of
3.0 mm pellets containing 17b-estradiol (1.7 mg/60-day release; Innovative
Research of America). Cells were injected 2 days after pellet implantation.
For tumor growth analysis, 4–5 3 106 cells were injected in to the mammary
fat pads of mice. Tumor development was monitored twice a week, and
tumor width (W) and length (L) were measured. Tumor volume was esti-
mated according to the formula V = p/6 3 L 3 W2. Mice were sacrificed
15–30 days after injection, and then tumors were excised and weighed.
For the experimental metastasis assay, 1–2 3 106 cells were injected into
the tail vein. Metastasis were examined later and analyzed macroscopically
and by hematoxylin and eosin (H&E) tissue staining. At least ten animals
were tested for each experimental condition. All experiments with miceqRT-PCR after cells were treated with control, ETS-1, ETV4 (PEA3), or GATA1
R-31 promoter fused to the luciferase reporter vector pGL4, as indicated in the
ciferase activities, expressed as relative luciferase units, were normalized to
directed mutagenesis was used to change the sequence of each or both of the
ith the indicated antibodies. Results are presented as in Figure 4B.
tween EMSY, ETS-1, and KDM5B in MCF-7 cells. Whole-cell extracts were
or preimmune GFP used as control IgG. The presence of EMSY, ETS-1, and
ol and KDM5B-siRNA-treated MCF-7 cells.
ed by qRT-PCR analysis in control and KDM5B-siRNA-treated MCF-7 cells.
cells were treatedwith siRNA against ETS-1, KDM5B, or a combination of both.
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Reverse Transcription and Quantitative Real-Time PCR
Total RNA and enriched miRNA fractions were obtained with miRNeasy Mini
(QIAGEN) andmirVANA kits (Ambion) according to the manufacturer’s instruc-
tions. DNase treatment was carried out in order to remove any contaminating
DNA. RNA was reverse transcribed with a miScript Reverse Transcription
Kit (QIAGEN) according to the manufacturer’s instructions. The real-time
qRT-PCR for the quantification of miRNAs (miRNA-31, miRNA-181a-2,
and miRNA-198) as well as pri-miRNAs (miR-31 pri-miRNA, miR-198 pri-
miRNA, and miR-181a-2 pri-miRNA) was carried out with a miScript Primer
Assays and miScript SYBR Green PCR Kit (QIAGEN) on an ABI 7500 Fast
Real-Time PCR System. Transcripts of RNU5A and RNU1A small RNAs
were also amplified in order to normalize the levels of miRNAs. All reverse tran-
scriptions and no-template controls were run at the same time. qRT-PCR was
used to determine the expression levels of EMSY, BRCA2, ETV4 (PEA3),
GATA1, ETS-1, KDM5B, KDM5A, FZD3, MMP-16, RHOA, RDX, ITGA5,
M-RIP, CXCL12, B2M, and ALAS1. B2M was amplified as an internal control
in order to monitor the amount and integrity of the cDNA. All reactions were
performed in duplicates. TheDDCtmethod was used for analysis. Fold change
expression in a sample = 2DDCt. Primers sequences are available upon
request. Gene expression changes are presented as relative fold change
compared to the values in empty vector cells (set at 1.0).
Real-Time-PCR-Based miRNA Expression Profiling
MCF-7 cells were analyzed for the presence and differential expression of
a panel of 88 cancer-related miRNAs with cancer RT2 miRNA PCR arrays
(RT2 Profiler; SABiosciences) according to the manufacturer’s instructions.
Data analysis was performed with the web-based software package for the
miRNA PCR array system.
Copy Number, Gene Expression, miRNA, and Survival Analysis of
Primary Tumors
In order to examine the relationship between EMSY amplification, miR-31
expression levels, and the expression of miR-31 targets, we employed the
METABRIC cohort of 2,000 primary breast tumors for which paired Affyme-
trix SNP 6.0 copy-number data and Illumina HT-12 expression data were
available. Data were processed and summarized as described by Curtis
et al. (2012). The genotype and expression data (Curtis et al., 2012) are avail-
able at the European Genome-phenome Archive (http://ebi.ac.uk/ega/), which
is hosted by the European Bioinformatics Institute, under accession numbers
EGAS00000000083. The raw noncoding RNA microarray data (Dvinge et al.,
2013) are available under accession number EGAS00000000122. Here, we
report on a subset of 1,283 cases for which we also had miRNA expression
profiles based on a custom Agilent platform (Dvinge et al., 2013). In brief,
miRNA data were processed by iteratively removing the two most extreme
outliers (on the basis of six replicates per probe) followed by cubic spline
normalization. Using these data, we evaluated the relationship between
EMSY amplification and miR-31 expression levels as well as the association
between these events and clinical outcome. EMSY copy-number states
were determined as previously described (Curtis et al., 2012). miR-31 expres-
sion levels were binned into low and high states on the basis of the lower
and upper 15% of expression values, respectively. Statistical significance
was evaluated with the log rank test. All analyses were performed in the R
statistical computing language. The Wilcoxon rank-sum test was used to
evaluate whether expression levels varied significantly depending on EMSY
copy-number state.
Real-time PCR of Tumor RNA
A representative subset of 98 primary tumors were selected from the
METABRIC cohort in order to include cases with EMSY amplification (n =
28), gain (n = 20), neutral copy number (n = 30), or heterozygous deletion
(n = 20). Cases were also selected to be copy-number neutral for IFNE1 and
MTAP, which flank the miR-31 locus. Then, qRT-PCR was performed in order
to assay EMSY and miR-31 expression levels as well as the expression of
the control miRNAs, miR-191, and miR-93. Triplicate aliquots of cDNA were816 Molecular Cell 53, 806–818, March 6, 2014 ª2014 The Authorssubjected to real-time qPCR on the ABI PRISM 7900HT system (Applied
Biosystems). Relative expression values accounting for differences in amplifi-
cation efficiency were calculated by automated software (SDS 2.3, Applied
Biosystems) using the linear regression of a standard titration curve included
for each plate. Expression was normalized for each sample by dividing the
relative expression of each gene by the geometric mean of the relative expres-
sion values of multiple internal reference genes.
50 RACE
RACE was carried out with an GeneRacer RLM-Race Kit (Invitrogen) accord-
ing to the manufacturer’s instructions. In brief, cDNAs were made from total
RNA (5 mg) with random primers according to the standard protocols. The 50
ends of the miRNAs were amplified with a gene-specific primer. Amplicons
were reamplified successively with nested-gene-specific primers. All PCRs
were performed with Platinum TaqDNA Polymerase High Fidelity (Invitrogen).
Amplified PCR products were purified and cloned into pCR4-Topo vectors
according to TOPO-TA cloning protocols, sequenced, and analyzed by
BLAST.
Luciferase Assay
Human miR-31 promoter was amplified by PCR from genomic DNA of MCF-7
cells. PCR products were digested and ligated into pGL4.10 (luc2; Promega).
Mutations were introduced by site-directed mutagenesis of the ETS-1 binding
sites according to the manufacturer’s instructions for site-directed muta-
genesis (Invitrogen). The pTK-luc (Renilla) vector was cotransfected with
the pGL4 (firefly) vectors in order to normalize the transfection efficiency. After
48 hr of transfection, the promoter activity was measured with a Dual-Glo
Luciferase Assay System (Promega) according to the manufacturer’s
protocol.
ChIP Analysis
Chromatin was prepared from MCF-7, and immunoprecipitations were per-
formed as described previously (Dawson et al., 2009) and with the ChiP-IT
High Sensitivity Kit (Active Motif) according to the manufacturer’s instructions.
Chromatin was immunoprecipitated with 2 mg of specific antibodies. Reverse
crosslinking of DNAwas followed byDNA purification with the ChIP DNAClean
& Concentrator kit (Zymo Research). The amount of DNA immunoprecipitated
with each antibody was measured in duplicate by qPCR. Primers sequences
are listed in Supplemental Experimental Procedures.
Endogenous Immunoprecipitations and Western Blot Analysis
MCF-7 cells were harvested by rinsing with PBS, and total extracts were incu-
bated at 4C overnight with the antibodies in IPH buffer (50 mM Tris [pH 8],
150 mM NaCl, 5 mM EDTA, and 0.5% NP-40 v/v). Standard procedures
were used for western blotting. For control western blotting of RNAi-treated
cells, antibodies against EMSY, ETS-1, KDM5B, and b-tubulin were used.
Finally, membranes were incubated with secondary antibodies conjugated
with horseradish peroxidase, and signals were visualized with enhanced
chemiluminescence (GE Healthcare). Images were scanned and processed
with Adobe Photoshop CS, and slight contrast was applied equally across
the entire images.
Invasion and Migration Assays
2.5 3 104 cells were plated in serum-free media in the upper chamber with
either non- or Matrigel-coated membranes (24-well insert; pore size, 8 mm;
BD Biosciences) for transwell migration and invasion assay, respectively.
The bottom chamber contained DMEM with 10% FBS. After 24–48 hr, the
bottom of the chamber insert was fixed and stained with crystal violet. Cells
on the stained membrane were counted under a microscope. Eachmembrane
was divided into four quadrants, and an average from all four quadrants was
calculated. Each assay was performed in biological triplicates.
Statistical Analysis
Statistical analysis was carried out with Microsoft Excel or in the R statistical
computing language in order to assess differences between experimental
groups. Statistical significances (Student’s t test) are expressed as a p value.
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